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Abstract
Objective. The observational RAPSODIA (RA, PsA and spondylitis including AS) study was planned to
assess, in patients with RA, AS and PsA, their involvement in medical decisions, quality of life and unmet
needs 15 years after the introduction of biologic therapies in Italy.
Methods. Patients completed a questionnaire during their scheduled rheumatology consultation. They rated
their satisfaction with disease knowledge on a 5-point scale (1 = not at all satisfied, 5 = totally satisfied). Self-
efficacy, defined as judgement of one’s own ability to achieve given levels of performance and exercise
control over events, was measured using the pain subscale of the Arthritis Self-Efficacy Scale. Patients’
global assessments of pain, fatigue and disease activity were recorded on 100 mm visual analogue scales
(0 = best status, 100 = worse status). Disease activity status was assessed using standard tools. Health
status was measured using the 36-item Short Form Health Survey and the Italian version of the HAQ.
Results. Ninety-eight per cent of patients reported that their health care practitioner used understandable
terms to explain their condition. Joint issues and general symptoms (e.g. fatigue and malaise) were
common. All measures of disease activity and self-efficacy scores were markedly better in patients
receiving biologic vs conventional therapy. Biologic therapy recipients were more productive at work.
Conclusion. These results confirm that some patients with rheumatic diseases are not satisfied with the
level of information they receive about their treatments. Biologic therapy appears to be an important ad-
vance, with patients receiving this form of treatment having improved symptoms and productivity. However,
patients still report unmet needs. Thus further research, and perhaps new and more effective therapies,
along with better education and multidisciplinary collaboration, are required to improve outcomes.
Key words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, quality of life, productivity, unmet
needs, biologic therapy, patient education.
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Introduction
Over the last decade patients have been encouraged to
take an active role in decision making about their care in
order to improve their clinical outcomes. To be involved in
this active decision-making process, patients need to be
informed about their disease and treatment options. At
present, widespread access to medical information via
the Internet makes it easier for patients, including patients
with rheumatic diseases, to obtain information [1].
RA, PsA and AS have a chronic course, require lifelong
management and have a negative impact on quality of life.
Recent data show that involving these patients in shared
decision making improves their outcomes, although RA
patients show significant gaps in disease knowledge
[24].
Improving work ability and maintaining overall quality of
life are important steps in rheumatic disease manage-
ment, together with controlling inflammation, alleviating
stiffness and pain and preventing joint deformity. Early
intervention significantly reduces the impact of chronic
inflammation and facilitates achievement of clinical remis-
sion, although the remission rates remain suboptimal and
radiographic progression occurs in about half of all RA
patients [14].
Satisfaction of RA patients with their care includes trust
in the physician and the professional health care staff.
Furthermore, asking patients to identify unmet needs fa-
cilitates the delivery of quality health care. On the other
hand, dissatisfaction with care is more common in pa-
tients who describe unmet health care needs, which
may be specific to different health care settings, making
generalizability difficult [16].
The observational RAPSODIA (RA, PsA and spondylitis
including AS) study was designed to evaluate the quality
of life and unmet needs in patients with RA, PsA or AS in
Italy. The aims were (i) to assess information delivery to
patients, (ii) to assess patient involvement in medical
decisions and (iii) to determine unmet health care needs
and how these relate to health status.
Methods
Study population
The multicentre RAPSODIA study was conducted at
16 sites in Italy. Patients were included if they were >18
years of age, had a diagnosis of RA, PsA or AS based on
standard criteria [79], had been receiving rheumatology
care for the previous 2 years and were able to read and
understand the Italian language. Patients were classified
into two groups: those receiving biologic therapy (biologic
treated) and those treated with conventional therapy but
eligible for biologic therapy because of inadequate or lack
of response (biologic eligible). The study was approved by
the local ethics committees, informed consent was ob-
tained from all patients prior to enrolment and the study
was conducted in accordance with good clinical practice
and the principles of the Declaration of Helsinki.
Data collection
Patients were asked to complete, anonymously and inde-
pendently, a specifically developed questionnaire during
their scheduled rheumatology consultation. There were 60
questions in 14 domains, including quality of life, time of
diagnosis, waiting time for appointments, disease aware-
ness, employment status, sources of information about
the disease, impact of both disease and therapy on quality
of life, participation in medical decision making and level
of satisfaction with their current anti-rheumatic therapies
and standard of care. Patients were also asked about sat-
isfaction with their knowledge of their disease on a 5-point
scale (1 = not at all satisfied, 5 = totally satisfied).
Self-efficacy, defined as judgement of one’s own ability
to execute given levels of performance and exercise con-
trol over events [10], was measured using the pain sub-
scale of the Arthritis Self-Efficacy Scale [11]. Patients’
global assessments of pain, fatigue and disease activity
were recorded on 100 mm visual analogue scales, with
scores ranging from 0 (no pain, fatigue or disease activity)
to 100 (highest levels of pain, fatigue or disease activity).
Disease activity status was assessed using the 28-joint
DAS (DAS28) [12] for RA and the BASDAI [13] for AS
and PsA. The patients’ current functional status was as-
sessed using the BASFI [14] for AS and PsA. Health status
was measured using the Medical Outcomes Study
36-item Short Form Health Survey (SF-36) [15, 16] and
the Italian version of the HAQ [17]. Age and disease dur-
ation were measured in years; sex, marital status, employ-
ment status and the presence of co-morbidity were
recorded as dichotomous variables.
Statistical analysis
Data were evaluated using parametric and non-paramet-
ric analysis. Continuous and ordinal data are presented as
median (range) and categorical data are shown as abso-
lute count and percentage. The unpaired MannWhitney U
test was used for between-group comparisons where
appropriate and Pearson’s and Spearman’s correlation
coefficients were calculated where indicated. The statis-
tical significance level was set at P= 0.01.
Results
Patients
A total of 743 patients were enrolled in the study. Fifty-
eight per cent were female, 42% were male, 250 patients
were 1845 years of age and 493 were >45 years of age.
The inflammatory arthropathy was RA in 327 patients, PsA
in 214 patients and AS in 200 patients.
Diagnosis
There was an average 4-year delay between the onset of
disease symptoms and diagnosis, independent of the
type of inflammatory arthropathy. Patients consulted a
variety of different health care professionals at symptom
onset, usually their primary care practitioner. However,
the diagnosis of RA, PsA or AS was almost exclusively
done by a rheumatologist.
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Understanding of disease, information and
involvement
The majority of patients (98%) reported that their general
practitioners explained their disease in understandable
terms. The other main sources of information used by pa-
tients were the Internet, television and newspapers. About
60% of enrolled patients needed more information, espe-
cially about diagnosis, medication, exercises and how to
improve performance of daily activities, and only about
one-third (37.1%) were satisfied with the information
provided during treatment. Fifty-one per cent of patients
reported good involvement in the process, with no differ-
ence between the various diseases. Self-efficacy scores
were consistently higher in biologic-treated patients
compared with those who were biologic eligible [RA
biologic-eligible patients 38.4 (range 10100) vs RA bio-
logic-treated patients 69.5 (range 10100), P< 0.01; PsA
biologic-eligible patients 36.9 (range 10100) vs PsA bio-
logic-treated patients 67.6 (range 10100), P< 0.01; AS
biologic-eligible patients 37 (range 10100) vs AS bio-
logic-treated patients 78.9 (range 10100), P< 0.01].
Symptoms, quality of life and work productivity
We identified the role of various symptoms in terms of
their impact on quality of life and their frequency is
shown in Table 1. Fatigue and malaise affected about
50% of patients. Other symptoms were tender and swol-
len joints (52%), reduced joint mobility (26%), back pain
(26%), walking difficulties (22%) and morning stiffness
(19%). Biologic-eligible patients experienced a signifi-
cantly higher average level of pain.
Although 97% of patients were in agreement with their
physicians about disease management, 72% felt that their
life was ruled by the disease and expressed frustration
about their disability. More than 60% were no longer
able to carry out normal activities, which strongly affected
their psychological well-being. In fact, anxiety was re-
ported by 57% of patients, 39% showed levels of irritabil-
ity and 21% reported sexual problems. Furthermore, work
performance was often impaired: employed patients lost
an average of 6 working days during the 3 months prior to
completion of the questionnaire, associated with an aver-
age 9.3% reduction in income. Overall, 34% of the pa-
tients reported difficulties at work, 11% had increased
work absenteeism and 7.9% retired from their job.
Therapy
Of the biologic-treated patients, 51% received adequate
information and participated in the therapy decision.
Furthermore, patients complied better with simplified
therapeutic regimens, and 69% of patients preferred
monthly s.c. therapy if efficacy was maintained.
Ninety-seven per cent considered the importance of
therapy for disease control. However, several disadvan-
tages were highlighted, related to injections, which were
the cause of malaise in 19% of patients, pain in 20% and
local irritation in 26%. It should be noted that satisfaction
with biologic therapies was higher than for conventional
treatments, paralleling the DAS in biologic-treated
patients compared with those who were biologic eligible
(Table 2).
Seventy-five per cent of biologic-treated patients re-
ported that their work performance increased during treat-
ment. The proportion of patients rating therapy as being
able to strongly ameliorate symptoms was 66% in those
who were biologic eligible and 94% among those who
were biologic treated. About the perceptions of biologic
therapy, 97% of patients thought that biologics slowed
disease progression, 96% thought these agents slowed
the progression of joint deformity, 95% thought they pro-
vided long-term relief, 93% said they had fewer relapses
and 91% reported a reduction in pain and swollen joints.
Discussion
Nearly all of the patients in this study reported that their
health care practitioner used understandable terms to ex-
plain their condition. A somewhat lower percentage was
satisfied with the information provided by their physician.
Data also showed that joint issues were common, as well
as fatigue and malaise. Both disease activity and self-
efficacy scores were significantly better in biologic-treated
patients, and biologic therapies improved the patients’
work ability.
A significant delay in diagnosis was observed, suggest-
ing that general practitioners need to identify potential
rheumatic patients as soon as possible and promptly
refer them to a specialist [2]. In Italy, many early arthritis
clinics have been established to evaluate patients in the
early stages of the disease, allowing intervention with dis-
ease-modifying therapies. The main symptoms observed
were fatigue and malaise, tender and swollen joints,
reduced joint mobility, back pain, walking difficulties and
morning stiffness, mirroring those reported in previous
studies [1].
Education is one of the cornerstones of care in rheum-
atic patients. Overall, nearly two-thirds of patients were
satisfied with the information provided by their physician,
confirming previously reported rates (68%). However, pro-
vision of information to patients with chronic diseases
such as RA, PsA and AS is not a simple or static process,
and information evolves over time [46]. Our data showed
that the main sources of information used by patients
were the Internet, television and newspapers, although
many patients were not satisfied with the level of informa-
tion they had.
Just over half of all patients (51%) stated that they had
good involvement in the process, with no difference be-
tween the different diseases. A patient-focused approach
based on the participation of patients in medical decision
making is associated with improved outcomes [6].
Furthermore, patients who are satisfied and involved in
their care are more compliant with treatment and experi-
ence fewer adverse outcomes [4]. Among biologic-treated
patients, 51% received adequate information and shared
decisions about therapy. Data show that patients comply
better with less complex therapeutic regimens and
that 69% of patients would prefer monthly s.c. therapy if
efficacy is maintained.
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Self-efficacy scores were consistently higher in bio-
logic-treated patients when compared with those who
were biologic eligible, the latter showing a significantly
higher average level of pain. Satisfaction with biologic
therapies was higher than for conventional treatments,
supporting current trends of earlier initiation of biologic
therapies in rheumatic diseases [16].
The ability to maintain work productivity is an important
issue for patients with rheumatic diseases. Three-quarters
of our biologic-treated patients increased their work per-
formance, mirroring the results from two large trials in pa-
tients receiving either adalimumab or etanercept [18, 19].
It is important to note that the cross-sectional design of
this study does not allow any inference of associations to
be made. Also, the questionnaire used was designed spe-
cifically for this study, limiting the generalizability of the
data obtained. It also needs to be pointed out that the
patients surveyed in this study were recruited from sec-
ondary care clinics. Nevertheless, these data provide
useful information on issues for patients with rheumatic
diseases in the Italian health care setting, supporting pre-
vious data that compared two different health care sys-
tems (Spanish vs Brazilian) in which larger investment in
the Spanish health care system provides higher quality of
life and better outcome in rheumatic patients [20].
In conclusion, the results of the RAPSODIA study show
that some Italian rheumatic patients are still not fully satis-
fied with the level of information they receive about their
treatments and confirm that biologics may improve symp-
toms and productivity in rheumatic patients. Further re-
search and new and more effective therapies, along with
better education and multidisciplinary collaboration, are
required to improve outcomes in these patients.
Rheumatology key messages
. Collaborative care improves outcomes in patients
with rheumatic diseases.
. Italian patients with rheumatic disease have a
number of unmet health care needs.
. Biologic therapy improves outcomes and work
productivity in patients with rheumatic diseases.
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TABLE 2 DASs in patients with RA, PsA or AS, according to their biologic therapy
Score
Biologic eligible,
median (range)
Biologic treated,
median (range)
P-value for between-group
comparisona
RA patients
DAS28 5.1 (3.96.2) 2.9 (2.43.5) <0.01
HAQ 2.3 (0.52.8) 0.8 (02.3) <0.01
SF-36
Physical function 45 (097) 72.5 (0100) <0.01
Role physical 20 (0100) 78.5 (0100) <0.01
Bodily pain 25.2 (098) 64 (20100) <0.01
Vitality 33.3 (085) 65.2 (093) <0.01
General health 39.5 (092) 45.5 (1289) <0.01
Social function 48.2 (0100) 90.2 (10100) <0.01
Mental health 58.2 (094) 70.2 (22100) <0.01
Role emotional 32.4 (0100) 90 (0100) <0.01
PsA and AS patients
BASDAI 68.71 (58.2472.28) 39.24 (35.1143.56) <0.001
BASFI 66.9 (10.295.3) 27.6 (085.2) <0.001
SF-36
Physical function 47 (093) 78.9 (098) <0.001
Role physical 29.4 (092) 87.8 (0100) <0.001
Bodily pain 22.5 (0100) 75 (18100) <0.001
Vitality 30.4 (081) 72 (0100) <0.001
General health 34.5 (098) 55.2 (1595) <0.001
Social function 47.9 (0100) 91.3 (1792) <0.001
Mental health 56.2 (098) 69.2 (30100) <0.001
Role emotional 35 (0100) 90 (0100) <0.001
aMannWhitney U-test; SF-36: Medical Outcomes Study 36-item Short Form Health Survey.
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